Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Total Liabilities (2016 - 2025)

Heron Therapeutics' Total Liabilities history spans 14 years, with the latest figure at $241.5 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 9.47% year-over-year to $241.5 million; the TTM value through Dec 2025 reached $241.5 million, down 9.47%, while the annual FY2025 figure was $241.5 million, 9.47% down from the prior year.
  • Total Liabilities reached $241.5 million in Q4 2025 per HRTX's latest filing, up from $234.1 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $266.8 million in Q4 2024 to a low of $114.7 million in Q1 2021.
  • Average Total Liabilities over 5 years is $242.2 million, with a median of $249.6 million recorded in 2022.
  • Peak YoY movement for Total Liabilities: skyrocketed 124.67% in 2021, then decreased 10.24% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $228.1 million in 2021, then rose by 4.05% to $237.4 million in 2022, then grew by 8.05% to $256.5 million in 2023, then grew by 4.02% to $266.8 million in 2024, then dropped by 9.47% to $241.5 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Total Liabilities are $241.5 million (Q4 2025), $234.1 million (Q3 2025), and $259.3 million (Q2 2025).